title: Effect of the angiotensin II type 1 receptor antagonist olmesartan on cerebral hemodynamics and rehabilitation outcomes in hypertensive post-stroke patients.
abstract: OBJECTIVE
  In patients with severe hypertension, chronic heart failure or history of stroke, the lower limit of cerebral blood flow (CBF) autoregulation is shifted to a higher blood pressure (BP) than in healthy subjects. This study investigated the effects of the angiotensin II receptor blocker (ARB) olmesartan on human cerebral haemodynamics and rehabilitation outcomes.
  
  
  METHODS
  Open treatment trial with pre-treatment and post-treatment evaluations.
  
  
  METHODS
  Olmesartan (10-20 mg) administered daily for 8 weeks.
  
  
  METHODS
  The 24-hour BP, clinical BP, CBF at rest, cerebrovascular reserve capacity (CRC) and rehabilitation outcomes (Brunnstrom stage, Barthel index and Mini-Mental State Examination [MMSE] score) were measured in 44 post-stroke patients with hypertension (62.2 +/- 10.7 years).
  
  
  RESULTS
  The systemic BP decreased after treatment compared with baseline. The CBF increased by 11.2% on the affected side and by 8.9% on the non-affected side of the brain and the CRC also increased on both sides. Improvements were observed in the Brunnstrom stage, Barthel index and MMSE score.
  
  
  CONCLUSIONS
  This study suggest that olmesartan has beneficial effects in post-stroke patients with hypertension and impaired CBF autoregulation and provides important information necessary to design future more definitive studies.
authors.affiliation: Department of Rehabilitation and Physical Medicine, Kagoshima University, Japan. shushu@m.kufm.kagoshima-u.co.jp
authors.forename: Shuji
authors.initials: S
authors.lastname: Matsumoto
authors.forename: Megumi
authors.initials: M
authors.lastname: Shimodozono
authors.forename: Ryuji
authors.initials: R
authors.lastname: Miyata
authors.forename: Kazumi
authors.initials: K
authors.lastname: Kawahira
mesh_terms: D000328:Adult; D000368:Aged; D047228:Angiotensin II Type 1 Receptor Blockers / Q000627:therapeutic use*; D000959:Antihypertensive Agents / Q000627:therapeutic use; D001794:Blood Pressure / Q000187:drug effects; D002560:Cerebrovascular Circulation / Q000187:drug effects* / Q000502:physiology; D005260:Female; D006801:Humans; D006973:Hypertension / Q000188:drug therapy*; D007093:Imidazoles / Q000627:therapeutic use*; D008297:Male; D008875:Middle Aged; D020521:Stroke / Q000150:complications; D000071939:Stroke Rehabilitation; D013777:Tetrazoles / Q000627:therapeutic use*; D055815:Young Adult
chemical_list: D047228:Angiotensin II Type 1 Receptor Blockers; D000959:Antihypertensive Agents; D007093:Imidazoles; D013777:Tetrazoles; C437965:olmesartan